BioSpace News Archive

Vistagen announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace.

Inmagene Biopharmaceuticals (“Inmagene” or the “Company”) today announced positive topline results from the multiple ascending dose (MAD) portion of its randomized, double-blind, placebo-controlled Phase 1 study of IMG-004, a potent, non-covalent, reversible, and brain permeable Bruton’s tyrosine kinase (BTK) inhibitor.

bioLytical Laboratories Inc. proudly announces its donation of 1,200 INSTI® HIV-1/2 Antibody Tests to KFF’s Greater Than AIDS campaign in support of National HIV Testing Day, June 27.

Bluejay Diagnostics, Inc. today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

Paragonix Technologies, a leader in organ transplant technology, proudly announces the PancreasPak™ Organ Preservation System, the first FDA-cleared device designed to protect and monitor donor pancreases during transportation.

Form Bio, the provider of advanced computational life sciences technology and PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced a range of new initiatives aimed at advancing and unifying the AAV industry.

Meitheal Pharmaceuticals, Inc. (“Meitheal”) today announced it has gained exclusive commercial rights in the U.S. to YUSIMRY® (adalimumab-aqvh), a biosimilar of Humira® (adalimumab), through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. (“HKF”).

SGD Pharma, global leader in glass pharmaceutical packaging, has published its latest 2023 Corporate Social Responsibility (CSR) Report illustrating the sustainable practices deeply embedded in its business ethos.

Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York.

Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the treatment of patients with platinum-resistant ovarian cancer.